Secondary damage in many injuries and diseases is often driven by apoptosis, a biochemical process that culminates in cell death. Modern therapeutic interventions interrupt primary injury but cannot reverse apoptosis.
Some injured cells can avoid cell death through a mechanism called apoptosis escape. Growth factors have been demonstrated to improve outcomes by enhancing apoptosis escape.
Our Smart Growth Factor™ Platform is designed to address the traditional challenges of growth factors as therapeutic targets. Specifically, our fusion proteins contain three domains:
Our lead asset, scp776, has shown efficacy in preclinical models of stroke, heart attack, and kidney injury. Scp776 is currently under investigation in a Phase II study in stroke patients.
